Neuromyelitis optica spectrum disorders

Current Neurology and Neuroscience Reports

Volumn 14, Issue 9, 2014, Pages

  Flanagan, Eoin P ^a   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aquaporin 4 IgG; Devic's disease; Optic neuritis; Transverse myelitis

Indexed keywords

AQUAPORIN 4; AQUAPORUMAB; AZATHIOPRINE; COMPLEMENT; COMPLEMENT INHIBITOR; CORTICOSTEROID; ECULIZUMAB; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN BINDING; BINDING AFFINITY; CLINICAL FEATURE; DEMOGRAPHY; DIAGNOSTIC IMAGING; DRUG RESPONSE; DRUG SAFETY; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; MAINTENANCE THERAPY; MOLECULAR PATHOLOGY; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACEUTICAL CARE; PLASMAPHERESIS; PREGNANCY; PROTEIN LOCALIZATION; PUERPERIUM; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; ANIMAL; HEAD; IMMUNOLOGY; METABOLISM; NEUROMYELITIS OPTICA; PATHOLOGY; SPINAL CORD;

ANIMALS; AQUAPORIN 4; HEAD; HUMANS; IMMUNOGLOBULIN G; NEUROMYELITIS OPTICA; SPINAL CORD;

EID: 84904219211     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0483-3     Document Type: Review

References (108)

1. Miyazawa I, Fujihara K, Itoyama Y. Eugene Devic (1858-1930). J Neurol. 2002;249(3):351-2.
2. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8. doi:10.1186/1742-2094-10-8.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12. doi:10.1016/S0140-6736(04) 17551-X. (Pubitemid 39626806)
4. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009;286(1-2):18-23. doi:10.1016/j.jns.2009.08.045.
5. Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012;69(8):1039-43. doi:10.1001/archneurol.2012.249.
6. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-80. doi:10.1001/archneurol.2012.314.
7. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18(1):5-10. doi:10.1177/1352458511431077.
8. Titulaer MJ, Hoftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411-28. doi:10.1002/ana.24117.
9. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008;65(5):629-32. doi:10.1001/archneur.65.5.629. (Pubitemid 351679657)
10. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834-49. doi:10.1093/brain/aws109.
11. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-14. (Pubitemid 29442132)
12. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol. 2012;69(8):1026-31. doi:10.1001/archneurol.2012. 112.
13. Elsone L, Townsend T, Mutch K, Das K, Boggild M, Nurmikko T, et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler. 2013;19(4):475-9. doi:10.1177/1352458512457720.
14. Kanamori Y, Nakashima I, Takai Y, Nishiyama S, Kuroda H, Takahashi T, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology. 2011;77(7):652-8. doi:10.1212/WNL. 0b013e318229e694.
15. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197-200. doi:10.1212/01.wnl.0000303817.82134.da.
16. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65(9):1479-82. doi:10.1212/01.wnl.0000183151.19351.82. (Pubitemid 41552787)
17. Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, Lennon VA, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010;68(5):757-61. doi:10.1002/ana.22121.
18. Baba T, Nakashima I, Kanbayashi T, Konno M, Takahashi T, Fujihara K, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol. 2009;256(2):287-8. doi:10.1007/s00415-009- 0139-4.
19. Suzuki K, Nakamura T, Hashimoto K, Miyamoto M, Komagamine T, Nagashima T, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol. 2012;69(10):1355-9. doi:10.1001/archneurol.2012.300.
20. Iorio R, Lucchinetti CF, Lennon VA, Costanzi C, Hinson S, Weinshenker BG, et al. Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology. 2011;77(17):1644-6. doi:10.1212/WNL. 0b013e3182343377.
21. Viegas S, Weir A, Esiri M, Kuker W, Waters P, Leite MI, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2009;80(6):679-82. doi:10.1136/jnnp.2008.157693.
22. Suzuki N, Takahashi T, Aoki M, Misu T, Konohana S, Okumura T, et al. Neuromyelitis optica preceded by hyperCKemia episode. Neurology. 2010;74(19):1543-5. doi:10.1212/WNL.0b013e3181dd445b.
23. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2013. doi:10.1177/1352458513507822.
24. Jarius S, Lauda F, Wildemann B, Tumani H. Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol. 2013;260(2):663-4. doi:10.1007/s00415-012-6755-4.
25. Hage Jr R, Merle H, Jeannin S, Cabre P. Ocular oscillations in the neuromyelitis optica spectrum. J Neuroophthalmol. 2011;31(3):255-9. doi:10.1097/WNO.0b013e31821d549b.
26. Takai Y, Misu T, Nakashima I, Takahashi T, Itoyama Y, Fujihara K, et al. Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology. 2012;79(17):1826-8. doi:10.1212/WNL.0b013e3182703ff7.
27. Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72(8):712-7. doi:10.1212/01.wnl.0000343001. 36493.ae.
28. Eichel R, Meiner Z, Abramsky O, Gotkine M. Acute disseminating encephalomyelitis in neuromyelitis optica: closing the floodgates. Arch Neurol. 2008;65(2):267-71. doi:10.1001/archneurol.2007.59. (Pubitemid 351240792)
29. Blanc F, Noblet V, Jung B, Rousseau F, Renard F, Bourre B, et al. White matter atrophy and cognitive dysfunctions in neuromyelitis optica. PLoS One. 2012;7(4):e33878. doi:10.1371/journal.pone.0033878.
30. Clardy SL, Lucchinetti CF, Krecke KN, Lennon VA, O'Toole O, Weinshenker BG, et al. Hydrocephalus in neuromyelitis optica. Neurology. 2014. doi:10.1212/WNL.0000000000000428.
31. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. doi:10.1186/1742-2094-9-14.
32. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603-5. doi:10.1212/01.wnl.0000254502.87233.9a.
33. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-9. doi:10.1212/01.wnl.0000216139.44259.74. (Pubitemid 43958540)
34. Asgari N, Skejoe HP, Lennon VA. Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient. Neurology. 2013;81(1):95-6. doi:10.1212/WNL.0b013e318297ef07.
35. Asgari N, Skejoe HP, Lillevang ST, Steenstrup T, Stenager E, Kyvik KO. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol. 2013;13:33. doi:10.1186/1471-2377-13-33.
36. Downer JJ, Leite MI, Carter R, Palace J, Kuker W, Quaghebeur G. Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete? Neuroradiology. 2012;54(4):279-85. doi:10.1007/s00234-011-0875-x.
37. Nakamura M, Miyazawa I, Fujihara K, Nakashima I, Misu T, Watanabe S, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol. 2008;255(2):163-70. doi:10.1007/s00415-008-0545-z.
38. • Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum. JAMA Neurol. 2014. This article reports that the initial myelitis episode in NMO/NMOSD is accompanied by a short lesion (fewer than three vertebral segments) in approximately 14% of cases, and when present this delays diagnosis/treatment. Certain clinical and radiological characteristics identified in this study may help select those with short myelitis lesions at highest risk of NMO/NMOSD. Therefore, short transverse myelitis lesions do not exclude AQP4-IgG testing nor NMOSD diagnosis.
39. Tanaka M, Tanaka K, Komori M, Saida T. Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. J Neurol Neurosurg Psychiatry. 2007;78(9):990-2. doi:10.1136/jnnp.2006.114165. (Pubitemid 47310840)
40. Braksick SA, Cutsforth-Gregory JK, Black DF, Weinshenker BG, Pittock SJ, Kantarci OH. Teaching NeuroImages: MRI in advanced neuromyelitis optica. Neurology. 2014;82(12):e101-2. doi:10.1212/WNL.0000000000000246.
41. Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol. 2013;33(2):123-7. doi:10.1097/WNO.0b013e318283c3ed.
42. Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009;66(3):425-8. doi:10.1002/ana.21753.
43. Makino T, Ito S, Mori M, Yonezu T, Ogawa Y, Kuwabara S. Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Scler. 2013;19(3):308-15. doi:10.1177/ 1352458512454772.
44. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566-9. doi:10.1002/ana.20770. (Pubitemid 43358081)
45. McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology. 2011;76(12):1108-10. doi:10.1212/WNL.0b013e318211c379.
46. • Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665-71. doi:10.1212/WNL. 0b013e318248dec1. discussion 669. This study demonstrates the greater sensitivity and specificity for NMO diagnosis with AQP4-IgG cell-based assays.
47. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197-204. doi:10.1212/WNL.0b013e3182a6cb5c.
48. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79(12):1273-7. doi:10.1212/WNL. 0b013e31826aac4e.
49. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-81. doi:10.1212/WNL.0000000000000101.
50. Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol. 2008;63(4):531-4. doi:10.1002/ana.21324. (Pubitemid 351614719)
51. Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54(1):38-50. doi:10.1002/ana.10587. (Pubitemid 36764980)
52. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78-83. doi:10.1001/archneurol.2007.17.
53. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1-2):82-90. doi:10.1016/j.jns.2011.03.038.
54. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535-44. doi:10.1016/S1474-4422(12)70133-3.
55. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149-64. doi:10.1111/cei.12271.
56. •• Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701-6. doi:10.1073/pnas.1017385108. This study shows that plasmablasts are the key B-cell subset that produces AQP4 autoantibodies in NMO; survival of plasmablasts is dependent on IL-6; these findings have led to trials of IL-6 receptor inhibitors in NMOSD.
57. Chihara N, Aranami T, Oki S, Matsuoka T, Nakamura M, Kishida H, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One. 2013;8(12):e83036. doi:10.1371/journal.pone. 0083036.
58. Steinman L. A rush to judgment on Th17. J Exp Med. 2008;205(7):1517-22. doi:10.1084/jem.20072066. (Pubitemid 351962013)
59. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450-61. (Pubitemid 34755161)
60. •• Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012;109(4):1245-50. doi:10.1073/pnas.1109980108. This study shows the differing effects of AQP4-IgG binding to its two dominant isoforms (M1 and M23) and demonstrates the impact of binding on water flux, highlighting the effect of AQP4-IgG binding at the cellular level.
61. Asavapanumas N, Ratelade J, Verkman AS. Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG. Acta Neuropathol. 2014;127(4):539-51. doi:10.1007/s00401-013-1204-8.
62. Zhang H, Verkman AS. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J Autoimmun. 2014. doi:10.1016/j.jaut.2014.02.011.
63. Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol. 2009;66(9):1164-7. doi:10.1001/archneurol.2009.188.
64. Ratelade J, Smith AJ, Verkman AS. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp Neurol. 2014;255:145-53. doi:10.1016/j.expneurol.2014.03.004.
65. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205(11):2473-81. doi:10.1084/jem.20081241.
66. Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71(3):323-33. doi:10.1002/ana.22686.
67. Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19(4):901-21. doi:10.1212/01.CON.0000433291.23091.65.
68. Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83-97. doi:10.1111/bpa.12099.
69. Lee DH, Metz I, Berthele A, Stadelmann C, Bruck W, Linker RA, et al. Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol Appl Neurobiol. 2010;36(7):685-7. doi:10.1111/j.1365-2990.2010.01105.x.
70. Matiello M, Kim HJ, Kim W, Brum DG, Barreira AA, Kingsbury DJ, et al. Familial neuromyelitis optica. Neurology. 2010;75(4):310-5. doi:10.1212/WNL. 0b013e3181ea9f15.
71. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;4, CD001331. doi:10.1002/14651858.CD001331.
72. Beck RW, Cleary PA, Anderson Jr MM, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326(9):581-8. doi:10.1056/ NEJM199202273260901.
73. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878-86.
74. Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int. 2012;2012:787630. doi:10.1155/2012/787630.
75. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501-4. doi:10.1177/1352458513495938.
76. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13(8):968-74. doi:10.1177/ 1352458507077189. (Pubitemid 351541430)
77. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. doi:10.1136/ard.2010. 144998.
78. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110-7. doi:10.1001/jamaneurol.2013.3071.
79. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659-66. doi:10.1212/WNL.0b013e31822a2780.
80. Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014. doi:10.1177/1352458514525870.
81. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128-33. doi:10.1001/archneurol.2009.175.
82. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-2. doi:10.1212/01.WNL.0000159399.81861.D5.
83. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-8. doi:10.1001/archneur.65.11.noc80069.
84. Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011;18(7):997-8. doi:10.1016/j.jocn.2010.12.011.
85. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84(8):918-21. doi:10.1136/jnnp-2012-304774.
86. Meyts I, Jansen K, Renard M, Bossuyt X, Roelens F, Regal L, et al. Neuromyelitis optica-IgG+ optic neuritis associated with celiac disease and dysgammaglobulinemia: a role for tacrolimus? Eur J Paediatr Neurol. 2011;15(3):265-7. doi:10.1016/j.ejpn.2010.09.005.
87. Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol. 2013;260(2):627-34. doi:10.1007/s00415-012-6692-2.
88. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006;63(7):957-63. doi:10.1001/archneur.63.7.957. (Pubitemid 44036296)
89. Bichuetti DB, Oliveira EM, Boulos Fde C, Gabbai AA. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol. 2012;69(7):938-9. doi:10.1001/archneurol.2012.545.
90. Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52(9):969-72.
91. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013;23(4):827-31. doi:10.1007/s10165-012-0715-9.
92. • Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302-6. doi:10.1212/WNL. 0000000000000317. This pilot study shows the potential benefits of IL-6 receptor monoclonal antibodies in NMOSD.
93. Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A, Yamamura T, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394-7. doi:10.1001/jamaneurol.2013.1246.
94. Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70(3):390-3. doi:10.1001/jamaneurol.2013.668.
95. Shetty A, Hanson R, Korsten P, Shawagfeh M, Arami S, Volkov S, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014;8:349-64. doi:10.2147/DDDT.S41437.
96. •• Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554-62. doi:10.1016/S1474-4422(13)70076-0. This open-label pilot study of eculizumab suggests that patients with NMOSD might benefit from eculizumab treatment. After prior studies suggested a role of complement in NMOSD pathogenesis, the promising results of a complement inhibitor brought this research from the bench to the bedside.
97. Matiello M, Pittock SJ, Porrata L, Weinshenker BG. Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. Arch Neurol. 2011;68(7):953-5. doi:10.1001/archneurol.2011.38.
98. Greco R, Bondanza A, Vago L, Moiola L, Rossi P, Furlan R, et al. Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Ann Neurol. 2014;75(3):447-53. doi:10.1002/ana.24079.
99. •• Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71(3):314-22. doi:10.1002/ana.22657. This is a proof-ofconcept study using a novel patient-derived human monoclonal antibody directed at AQP4 engineered for being incapable of generating complement and cell-mediated cytotoxicity. The monoclonal antibody abrogated NMO lesions in a mouse model of NMO.
100. Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79(10):696-701. doi:10.1002/bdra.20399. (Pubitemid 47584193)
101. Kim W, Kim SH, Nakashima I, Takai Y, Fujihara K, Leite MI, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78(16):1264-7. doi:10.1212/WNL.0b013e318250d812.
102. Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler. 2013;19(11):1544-7. doi:10.1177/1352458513498125.
103. Pellkofer HL, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler. 2009;15(8):1006-8. doi:10.1177/1352458509106512.
104. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012;18(10):1480-3. doi:10.1177/1352458512439439.
105. Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology. 2012;79(10):1065-6. doi:10.1212/WNL.0b013e31826845fe.
106. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18(1):113-5. doi:10.1177/1352458511431973.
107. Collongues N, Cabre P, Marignier R, Zephir H, Papeix C, Audoin B, et al. A benign form of neuromyelitis optica: does it exist? Arch Neurol. 2011;68(7):918-24. doi:10.1001/archneurol.2011.127.
108. Flanagan EP, Aksamit AJ, Kumar N, Morparia NP, Keegan BM, Weinshenker BW. Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. Neurol Clin Pract. 2013;3(5):448-51. doi:10.1212/CPJ. 0b013e3182a78f82.